ArticleGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2026
Progression in familial exudative vitreoretinopathy: Long-term clinical course and baseline predictors.
Article in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo characterise the long-term clinical course of familial exudative vitreoretinopathy (FEVR) and identify baseline clinical features associated with disease progression.
methodsIn this retrospective cohort study, 191 eyes of 120 patients with FEVR and ≥ 3 years of follow-up at a tertiary referral centre were analysed. Progression was defined as worsening of clinical stage or development of increased exudation or vitreoretinal traction requiring treatment. Baseline clinical and angiographic features were evaluated using logistic regression. A prespecified subgroup analysis was performed in advanced-stage eyes (stages 3-4) to compare treatment approaches.
resultsProgression occurred in 40 eyes (21%) over a mean follow-up of 78.9 ± 41.1 months, most frequently within the first year (55% of progressing eyes) but also observed up to 6 years (range 2-72 months). In multivariable analysis, the presence of a telangiectatic capillary network was the only independent predictor of progression (P < 0.001). In advanced-stage disease, vitreoretinal surgery was associated with lower odds of progression compared with laser photocoagulation after adjustment for baseline characteristics (adjusted OR 0.21; 95% CI 0.05 to 0.86; P = 0.029). Pathogenic variants were most commonly identified in LRP5 and FZD4.
conclusionDisease progression in FEVR occurs most frequently within the first year but may develop years later. A baseline telangiectatic capillary network is a strong independent predictor of progression. In advanced-stage disease, vitreoretinal surgery may be associated with a lower risk of progression compared with laser monotherapy.
Indexed as
Identifiers
42635748What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.